NovaBridge Biosciences director files initial holdings

NovaBridge Biosciences director and officer Cao Sean Wuxiong filed an initial ownership report showing existing equity awards and share holdings.

Rhea-AI Filing Summary

NovaBridge Biosciences director and officer Cao Sean Wuxiong filed an initial ownership report showing existing equity awards and share holdings. He reports employee share options over 19,370 Ordinary Shares at an exercise price of $1.17 per share expiring on May 28, 2035, and options over 408,929 Ordinary Shares at $4.65 per share expiring on September 3, 2035.

He also holds 408,933 restricted share units, each representing a contingent right to receive one ADS, which vest over four years from a September 3, 2025 grant date. In addition, he reports direct ownership of 56,472 Ordinary Shares. The filing reflects holdings only and does not show new open‑market purchases or sales.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Cao Sean Wuxiong

Role See Remarks

Type	Security	Shares	Price	Value
holding	2025 Employee Share Option (right to buy)	--	--	--
holding	2025 Employee Share Option (right to buy)	--	--	--
holding	Restricted Share Units	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: 2025 Employee Share Option (right to buy) — 428,299 contracts (Direct); Restricted Share Units — 408,933 contracts (Direct); Ordinary Shares — 56,472 shares (Direct)

Footnotes (6)

1. F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. F2. Reported securities are represented by 24,553 ADSs.
3. F3. Number of underlying securities and exercise price expressed in terms of ADSs.
4. F4. The option was granted on May 28, 2025 and is vested and exercisable. Amount of underlying securities excludes a portion of the option that was forfeited upon the Reporting Person's appointment as an officer of the Issuer.
5. F5. The option was granted on September 3, 2025. The option vests and becomes exercisable, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADSs (based on trading days only) is at or above US$8.00.
6. F6. On September 3, 2025, the Reporting Person was granted 408,933 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Cao Sean Wuxiong’s Form 3 for NovaBridge Biosciences (NBP) disclose?

It discloses Cao Sean Wuxiong’s existing equity stake in NovaBridge Biosciences, including stock options, restricted share units, and Ordinary Shares. This is an initial ownership statement and does not report any new open‑market buying or selling activity.

How many stock options does Cao Sean Wuxiong hold in NovaBridge Biosciences (NBP)?

He reports options over 19,370 Ordinary Shares at $1.17 per share expiring in 2035, and options over 408,929 Ordinary Shares at $4.65 per share, also expiring in 2035. These awards give him the right to buy shares at fixed prices.

What restricted share units (RSUs) are reported for NovaBridge Biosciences (NBP)?

The filing shows 408,933 restricted share units granted on September 3, 2025. Each RSU represents a contingent right to receive one ADS, vesting over four years, with one‑fourth after one year and the remainder in 12 quarterly installments.

How many NovaBridge Biosciences (NBP) Ordinary Shares does Cao Sean Wuxiong own directly?

He reports direct ownership of 56,472 Ordinary Shares. These are separate from his option awards and RSUs, and represent shares he already holds rather than rights to acquire additional stock in the future.

Are the NovaBridge Biosciences (NBP) securities represented by American Depositary Shares (ADSs)?

Yes. A footnote explains that Ordinary Shares may be represented by ADSs, with each 10 ADSs representing 23 Ordinary Shares. Another footnote notes that the reported securities correspond to 24,553 ADSs based on this representation structure.

Does Cao Sean Wuxiong’s NovaBridge Biosciences (NBP) filing show recent trades?

No. The entries are labeled as holdings, and the transaction summary shows no buy or sell transactions. It records outstanding options, RSUs, and Ordinary Shares rather than new market purchases, sales, or exercises on the reported date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:37 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cao Sean Wuxiong

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	56,472(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2025 Employee Share Option (right to buy)	(4)	05/28/2035	Ordinary Shares(1)	19,370(3)(4)	$1.17(3)	D
2025 Employee Share Option (right to buy)	(5)	09/03/2035	Ordinary Shares(1)	408,929(3)	$4.65(3)	D
Restricted Share Units	(6)	(6)	Ordinary Shares(1)	408,933(3)	(6)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 24,553 ADSs.

3. Number of underlying securities and exercise price expressed in terms of ADSs.

4. The option was granted on May 28, 2025 and is vested and exercisable. Amount of underlying securities excludes a portion of the option that was forfeited upon the Reporting Person's appointment as an officer of the Issuer.

5. The option was granted on September 3, 2025. The option vests and becomes exercisable, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADSs (based on trading days only) is at or above US$8.00.

6. On September 3, 2025, the Reporting Person was granted 408,933 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.

Remarks:

Chief Business Development Officer and Director Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)